Nektar Therapeutics (NKTR) Capital Expenditures (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Capital Expenditures of $18000.0 for Q1 2026, up 800.0% year-over-year from $2000.0 in Q1 2025, and little changed quarter-over-quarter from $18000.0 in Q4 2025.
Powered by 
Analysis
Nektar Therapeutics (NKTR) Capital Expenditures (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $18000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 800.0% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at $187000.0 (down 85.76% YoY), while the FY2025 annual figure was $171000.0, down 88.35% from the prior year.
- Capital Expenditures for Q1 2026 stood at $18000.0, roughly flat from $18000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $4.2 million in Q1 2022, with the low at $2000.0 in Q1 2025.
- The 5-year median for Capital Expenditures is $181000.0 (2022), against an average of $482235.3.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures soared 1918.18% in 2024, then plunged 98.73% in 2025.
- Nektar Therapeutics' Capital Expenditures stood at $512000.0 in 2022, then plunged by 53.71% to $237000.0 in 2023, then surged by 93.67% to $459000.0 in 2024, then tumbled by 96.08% to $18000.0 in 2025, then changed by 0.0% to $18000.0 in 2026.
- Business Quant data shows NKTR's Capital Expenditures at $18000.0 in Q1 2026, $18000.0 in Q4 2025, and $114000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn | 94,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 94,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Sep 30, 2025 | 114,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 459,000.00 |
| Sep 30, 2024 | 666,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Dec 31, 2023 | 237,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Jun 30, 2023 | 162,000.00 |
| Mar 31, 2023 | 433,000.00 |
| Dec 31, 2022 | 512,000.00 |
| Sep 30, 2022 | 181,000.00 |
| Jun 30, 2022 | 780,000.00 |
| Mar 31, 2022 | 4.20 Mn |
| Dec 31, 2021 | 5.90 Mn |
| Sep 30, 2021 | 2.94 Mn |